Document Headings

                    Document headings vary by document type but may contain                    the following:                  
                -                       the agency or agencies that issued and signed a document                    
                -                       the number of the CFR title and the number of each part                      the document amends, proposes to amend, or is directly                      related to                    
                -                       the agency docket number / agency internal file number                    
                -                       the RIN which identifies each regulatory action listed in                      the Unified Agenda of Federal Regulatory and Deregulatory                      Actions                    

                    See the                                          Document Drafting Handbook                                        for more details.                  

###### Department of Health and Human Services

###### Food and Drug Administration

          - [Docket No. FDA-2023-N-1506]

# AGENCY:

Food and Drug Administration, HHS.

# ACTION:

Notice.

# SUMMARY:

                        The Food and Drug Administration (FDA) is announcing the availability of a summary on the comments received for the “Methodological Challenges Related to                               ( print page 86344)                            Patient Experience Data; Request for Information and Comments” notice published on May 2, 2023. The input received in response to the Request for Information will help FDA plan two public workshops focused on methodological challenges and will help FDA identify priorities for future work.                    

# FOR FURTHER INFORMATION CONTACT:

                        Ethan Gabbour, Center for Drug Evaluation and Research, Food and Drug Administration, 10903 New Hampshire Ave., Bldg. 51, Rm. 6306, Silver Spring, MD 20993, 301-796-8112,                         *Ethan.Gabbour@fda.hhs.gov.*

# SUPPLEMENTARY INFORMATION:

## I. Background

                    Under the seventh iteration of the Prescription Drug User Fee Act, incorporated as part of the FDA User Fee Reauthorization Act of 2022, FDA committed to facilitate the advancement and use of systematic approaches to collect and utilize robust and meaningful patient and caregiver input that can more consistently inform drug development and, as appropriate, regulatory decision making. This included issuing a Request for Information (RFI) available at                     *https://www.federalregister.gov/​documents/​2023/​05/​02/​2023-09265/​methodological-challenges-related-to-patient-experience-data-request-for-information-and-comments*                     to elicit public input on methodologic challenges related to patient experience data encountered by stakeholders, and other areas of greatest interest or concern to public stakeholders.[1]                                          The RFI was published on May 2, 2023, and the public comment period was open until July 3, 2023. A summary of the comments received can be found in the in the public docket or by going to                     *https://www.regulations.gov*                     and entering the following docket number: FDA-2023-N-1506.                

## II. Electronic Access

                    Persons with access to internet may obtain the summary within the public docket at                     *https://www.regulations.gov/​docket/​FDA-2023-N-1506.*

Dated: December 8, 2023.

Lauren K. Roth,

Associate Commissioner for Policy.

# Footnotes

1.                             The Federal Food, Drug, and Cosmetic Act, as amended by the 21st Century Cures Act (Pub. L. 114-255) and the FDA Reauthorization Act of 2017 (FDARA) (Pub. L. 115-52), defines patient experience data as data that are collected by any persons (including patients, family members and caregivers of patients, patient advocacy organizations, disease research foundations, researchers and drug manufacturers) and are intended to provide information about patients' experiences with a disease or condition, including the impact (including physical and psychosocial impacts) of such disease or condition or a related therapy or clinical investigation and patient preferences with respect to treatment of the disease or condition.                    
        Back to Citation      

[FR Doc. 2023-27312 Filed 12-12-23; 8:45 am]

BILLING CODE 4164-01-P